Avanzanite Bioscience Expands Partnership With Advicenne in Additional European Countries
Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”), a specialty pharmaceutical company with a corporate mission of boosting orphan drug access and unlocking their full potential in European markets, today announced that it has expanded its commercial partnership with Paris-based specialty pharmaceutical company Advicenne for Sibnayal®.
- Avanzanite Bioscience B.V. (“Avanzanite” or the “Company”), a specialty pharmaceutical company with a corporate mission of boosting orphan drug access and unlocking their full potential in European markets, today announced that it has expanded its commercial partnership with Paris-based specialty pharmaceutical company Advicenne for Sibnayal®.
- Today’s announcement extends Avanzanite’s exclusive commercialization and distribution rights into three additional European countries, including Ireland, Cyprus and Malta.
- The condition leads to stunted growth in children, brittle bones or rickets, kidney stones and life-threatening hypokalemia.
- Announced in February 2023 , the original geographic scope of the partnership included Germany, Austria, Switzerland and Greece.